ACEi reduces hypertension-induced hyperinflammation in COVID-19

Nature Reviews Cardiology, Published online: 18 January 2021; doi:10.1038/s41569-021-00512-9Antihypertensive therapy, particularly with the use of an angiotensin-converting enzyme inhibitor, improves outcomes in patients with hypertension and SARS-CoV-2 infection, who are susceptible to hyperinflammation and severe outcomes with COVID-19.

Source: Nature Reviews Cardiology - January 18, 2021 Category: Cardiology Authors: Gregory B. Lim Source Type: research